Noninvasive Evaluation of Hepatic Fibrosis Using Serum Fibrotic Markers, Transient Elastography (FibroScan) and Real-Time Tissue Elastography
Chie Tatsumi(Kindai University), Mitake Takeshi(Hitachi (Japan)), Satoshi Kitai(Kindai University), Yasunori Minami(Kindai University), Shunsuke Takahashi(Kanagawa Dental University), Hobyung Chung(Kindai University), Kazuomi Ueshima(Kindai University), Tatsuo Inoue, Kenji Fujimoto(National Hospital Organization), Akiko Tonomura(Hitachi (Japan)), Kiyoshi Maekawa(Kindai University), Masatoshi Kudo(Kindai University)
Cited by 110
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Development of a Prokaryotic Universal Primer for Simultaneous Analysis of Bacteria and Archaea Using Next-Generation Sequencing
|PLoS ONE|2014|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k